Escalating growth of several chronic diseases in China has prompted the government to undertake several programs to improve the healthcare scenario in the country. Through the healthcare reforms, the government of China is involved in activities for improving local medical infrastructure, expansion of public health service programs and health insurance and the establishment of a National Essential Drug List are widening the healthcare coverage considerably in China. Additionally, provision of low-cost and basic health amenities provided by the government are proving to be worthwhile in tackling the growing burden of diseases in China.
The government of China extends its support towards diagnosis and treatment of diabetes in the country. With several programs including the National Plan for Chronic Disease Prevention and Treatment (2012-15) and various collaborations with insulin companies for diabetes screening are being given special attention by the government.
“Government initiatives have been a key to increasing diagnosis of diabetes in the country, thereby increasing consumption of insulin in the country”– according to the research report ‘China Insulin Market Review to 2018 - Increasing Focus on R&D Investments’ by Ken Research.
The report provides detailed overview of the sales of various types of insulin in China and helps readers in identifying the ongoing trends in the key segments of the industry and anticipated growth in future depending upon changing industry dynamics in coming years. The report will aid industry consultants, insulin distributors, marketing companies and other stakeholders to align their market centric strategies according to ongoing and expected trends in future.